• TGN1412 induced T-cell activation following high density preculture of PBMCs is a consequence of FcγRIIb upregulation on monocytes.
Introduction
Immunostimulatory monoclonal antibodies (mAb) targeting T-cell co-stimulatory molecules are an emerging class of therapeutics designed to promote either endogenous or vaccinemediated anti-cancer T-cell immunity. While cited as a major leap forward in the clinical use of mAb, they are often associated with severe side effects including autoimmunity and inflammatory reactions resulting from cytokine release syndrome (CRS) 1 .
CD28 is a key co-stimulatory molecule on T cells which drives T-cell activation alongside TCR engagement. There has been a keen focus on the development of therapeutic anti-CD28 mAb for a range of diseases including autoimmunity and cancer [1] [2] [3] . However, anti-CD28 mAb suffered a major setback when the first-in-man trial of TGN1412 caused life-threatening CRS 1 . TGN1412, a so-called 'superagonist', is able to stimulate T-cell activation without TCR engagement 4 . Preclinical in vitro testing using human PBMCs and in vivo testing in cynomolgus macaques failed to predict this toxicity. Later evaluations revealed that macaques lack CD28 on effector memory T-cells and so were unable to respond 5 . In addition, further species differences were observed in rodent models where CD28 superagonist mAb had been found to preferentially activate regulatory T cells 3, 6 .
Following these failures, there has been a concerted effort to develop predictive in vitro assays that allow a better understanding of the in vivo action of superagonists and their preclinical prediction. The immobilisation of TGN1412 onto plastic or the addition of antiIgG antibody have been shown to induce cytokine release in PBMC assays 6, 7 . Both approaches provide extensive cross-linking of the mAb on the T-cell surface. In assays with soluble TGN1412, such cross-linking could be provided by co-engagement of the mAb Fc
For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From region with Fcγ receptors (FcγR) expressed on various PBMC cell subsets. The inability of soluble TGN1412 to mediate cytokine release suggests that unmanipulated PBMCs lack sufficient capacity to allow TGN1412 to induce T-cell activation. Co-culture of T cells with human umbilical vein endothelial cells (HUVECs) has also been shown to induce T-cell activation in response to TGN1412, although the level of cytokine release was low and surprisingly the interaction of the mAb Fc region with FcγRs was not required 8 .
In an interesting alternative approach to demonstrating TGN1412 activity in vitro, Romer et al 9 showed that soluble TGN1412 is able to stimulate cytokine release after preculturing
PBMCs at high density (HD) for 48 hours, and proposed that this was due to an increase in the 'tonic activation' of the responder T cells which decreases their threshold for stimulation.
In our study we have used this HD preculture protocol to investigate the role of FcγRs in the activation of T cells by a TGN1412. We show that HD preculture induces a remarkable increase in the expression of FcγRIIb on monocytes, but not B cells, and that this provides sufficient interactions with the Fc region of TGN1412 to induce T-cell activation. In contrast to previous studies 9, 10 our observations indicate that no enhancement of T-cell sensitivity is required, whereas co-engagement with FcγRIIb is crucial to the agonistic activity of soluble TGN1412. These findings provide an insight into the cellular and molecular requirements for superagonistic activity in the context of targeting CD28 with mAb and have important implications for mAb designed to enhance T-cell responses.
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Materials and Methods

Donors and PBMC preparation
Anonymised leukocyte cones were from the National Blood Service (Southampton, UK) and used within 4 hours for preparation of PBMCs by density gradient centrifugation TGN1412 was produced using published sequences (US patent number US 7,585,960).
Variable regions were sub-cloned into expression vectors (pEE6.4 heavy chain and pEE12.4 light chain, Lonza) containing constant regions of human IgG4. Heavy and light chain vectors were sub-cloned together before transfection into 293F cells for transient or CHO-K1 cells for stable production. mAb was purified on Protein A-Sepharose and aggregates removed by gel filtration. Preparations were endotoxin low (<1 ng/mg protein) (Endosafe-PTS, Charles River Laboratories). Preparation of F(ab') 2 from IgG was as described previously 12 .
Cell culture and T-cell proliferation assays
Cell culture was in serum-free medium (CTL-Test™ Medium, CTL Europe GmbH, Bonn) supplemented with glutamine (2 mM), pyruvate (1 mM), penicillin and streptomycin (100 IU/ml) at 37 °C, 5 % CO 2 .
Fresh PBMCs were labelled with 2 μM carboxyfluorescein succinimidyl ester (CFSE). For HD preculture, cells were cultured in a 24-well plate at 1 x 10 7 /ml as described by Romer et 
T cell, B cell and monocyte isolation
Cell fractions were isolated from CFSE-labelled PBMCs by negative selection using EasySep for B cells and T cells (STEMCELL Technologies) and MACS for monocytes (Miltenyi Biotec).
Cytokine determination
Supernatants were taken 48 hours post-stimulation and cytokines determined using the Vplex Proinflammatory Panel 1 (human) kit (Meso Scale Discovery, Rockville, MD).
Flow cytometry
FcγRIIb on monocytes and B cells was determined using anti-CD19-APC-Cy7, anti-CD14- 
Western Blot
Monocytes were isolated from HD and LD precultured PBMCs, resuspended in lysis buffer and processed as previously 13 . Membranes were probed with rabbit anti-human FcγRIIb (Abcam), goat anti-rabbit IgG HRP F(ab') 2 and the signal visualised using enhanced chemiluminescence (GE Healthcare Lifesciences).
Transfection of CHO-K1 cells
CHO-K1 cells were transfected with FcγRIIb in plasmid pcDNA3, selected using 1mg/ml geneticin (Life Technologies) and screened by flow cytometry using the pan-FcγRII mAb AT10 F(ab') 2 -FITC (in-house). Positive colonies were expanded and sorted using a FACSAria II (BD Biosciences).
Statistics
Statistical analysis was performed using a 2-tailed Spearman-Rank correlation on Graphpad Prism version 6 software.
Results
T-cell proliferation and cytokine responses induced by anti-CD28 and anti-CD3 mAb differ before and after high density preculture CD28 superagonistic mAb induce polyclonal T-cell activation in vitro, independent of TCR engagement 14, 15 . TGN1412 was produced from the patented sequence. PBMCs from a large panel of donors were used to assess T-cell proliferation induced by soluble TGN1412
(hIgG4), a second anti-CD28 superagonist, 28.1 (mIgG1), and the anti-CD3 mAb OKT3
(mIgG2a) and UCHT1 (mIgG1) before and after high density (HD) preculture. With fresh PBMCs, anti-CD3 mAb induced predominantly CD8 + T-cell division whereas 28.1 induced predominantly CD4 + T-cell division ( Figure 1A ). TGN1412 induced a very low or no response in fresh PBMCs ( Figure 1A ), as has been reported previously 6 . However, after
PBMCs were precultured at HD for 48 hours as described by Romer et al 
Inhibition of T-cell proliferation by anti-FcγR mAb
To investigate the requirement for FcγR co-engagement by TGN1412, we used a panel of (mIgG2a) requires FcγRI, whereas UCHT1 (mIgG1) requires FcγRIIa ( Figure 3A ). In contrast, we found that TGN1412 activity was inhibited by the anti-FcγRIIb mAb 6G11
( Figure 3A ) and this was confirmed in 8 donors ( Figure 3B ).
Monocytes and B cells from high density cultures confer responsiveness to TGN1412
To investigate which immune cells were capable of restoring TGN1412-responsiveness to response was not reached until a B:T cell ratio of more than 0.1:1, monocytes induced a response at a ratio of 0.02:1 ( Figure 3D ).
Expression of FcγRIIb is increased on high density precultured monocytes
The finding that the TGN1412-response could be restored by monocytes as well as B cells, and that this response was blocked by anti-FcγRIIb was unexpected as FcγRIIb is expressed on only a fraction of monocytes and at very low density 19 . We then compared the expression (Figure 3 ), these data explain how monocytes from HD precultures are able to engage with and cross-link TGN1412 through FcγRIIb.
T cells do not require high density preculture to respond to TGN1412 in the presence of high density precultured monocytes It has previously been suggested that changes in the activation state of T cells themselves might be responsible for the responsiveness to TGN1412 after HD preculture 9 . We next examined whether the changes we observed in the monocytes alone were sufficient. T cells were isolated from PBMCs after HD preculture and their response to TGN1412 in the presence of monocytes from autologous HD and LD precultured PBMCs was compared ( Figure 5A ). With monocytes from HD precultures, TGN1412 induces T-cell proliferation comparable with that in total PBMCs whereas it induces only a very low level of stimulation with monocytes from LD preculture. In contrast, T cells responded to OKT3 with both LD and HD precultured monocytes, and in many donors responses were higher with the LD monocytes. We also determined the response of T cells isolated from PBMCs after LD preculture in the presence of the HD and LD monocytes ( Figure 5B ). Importantly, with monocytes from HD preculture, T cells from LD preculture gave responses to TGN1412 that were comparable with those of the HD T cells, but they gave no response with monocytes from LD preculture. In both cases, the response was blocked by anti-FcγRIIb mAb. These results strongly point to the ability of T cells to respond to TGN1412 after HD preculture being primarily due to an increase in t 20 he availability of FcγRIIb on monocytes, rather than an increase in the responsiveness of the T cells themselves. This was supported by the finding that T cells isolated from fresh PBMCs were responsive to TGN1412 in the presence of autologous HD but not LD precultured monocytes (Supplementary Figure 5) .
Fresh T cells respond to TGN1412 in the presence of sufficient FcγRIIb
In Figure 3 we showed that when co-cultured with B cells at a high B:T cell ratio, T cells isolated from HD preculture were responsive toTGN1412 . Since the level of FcγRIIb on B cells is unchanged by HD preculture (Figure 4) , we next determined whether fresh T cells were also responsive to TGN1412 when co-cultured with B cells at a similarly high ratio.
The results in Figure 6A show clearly that in the presence of B cells, fresh T cells were responsive to TGN1412. In contrast fresh T cells did not respond to TGN1412 when cocultured with fresh monocytes, consistent with the monocytes lack of FcγRIIb. However, these monocytes were able to induce a T-cell response to OKT3, consistent with its requirement for FcγRI. 
Discussion
In this study we show that HD preculture of PBMCs induces an exponential increase in the expression of FcγRIIb by monocytes, and that this is a prerequisite for mediating the superagonistic activity of TGN1412 in vitro. Our findings add to the growing body of evidence showing the importance of Fc-FcγRIIb interactions for the activity of agonistic mAb [21] [22] [23] . In these experiments we did not observe any change in the sensitivity of the T cells themselves to TGN1412 following HD preculture, in contrast to previous studies which suggested the HD preculture resulted in enhanced tonic TCR signalling causing a reduction in the activation threshold of the T cells in vitro 24, 25 . On-going studies show that other immunostimulatory mAb, including anti-OX40 and -4-1BB, show similar HD preculture dependency for increased activatory activity (data not shown) suggesting that this assay will have considerable utility for predicting the potency and perhaps toxicity for many FcγRIIb-dependent agonistic mAb.
Lühder et al, proposed that anti-CD28 superagonists oligomerize CD28 on the T-cell surface and that the position of the recognised epitope influences the proximity of intracellular effector molecules leading to TCR-independent T-cell activation 4 . We postulate that this increase in FcγRIIb following HD preculture enables efficient clustering of CD28 on the Tcell surface which presumably mimics the activity of CD80/CD86 at the APC: T cell synapse leading to T-cell activation.
In our experiments TGN1412 F(ab') 2 failed to induce T-cell proliferation or cytokine release in accordance with findings by Ball et al
26
. However, a recent study reported that TGN1412 F(ab') 2 still induces residual intracellular TNFα expression in T cells at 0.5ug/mL 10 . The reason for this discrepancy is unclear. Taken together, these findings suggest that TGN1412
should be defined as an FcγR-dependent superagonist. In contrast, the activity of a second anti-CD28 mAb, 28.1, appears to be independent of FcγR interaction and so should be considered a "true" superagonist.
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Our data supports a mechanism by which HD monocytes mediate TGN1412 activity as a result of their dramatically increased FcγRIIb expression and the extent of proliferation and cytokine release correlates with the level of FcγRIIb. This upregulation was observed on both monocytes from HD PBMC cultures and on HD precultured isolated monocytes (data not shown). FcγRIIb expression on HD monocytes was higher than on HD B cells ( Figure 4B) and predominantly of the b2 isoform ( Figure 4C ). In vitro, both IL-4 and IL-10 have been
shown to drive the upregulation of FcγRIIb on monocytes although they increased expression of both the b1 and b2 isoforms [27] [28] [29] . However, we did not see any increase in the levels of IL-4 or IL-10 when comparing supernatants from LD and HD precultures (data not shown)
and it remains to be seen what is responsible for the increase in monocyte FcγRIIb expression.
In the presence of monocytes from HD precultures, T cells from LD precultures gave responses to TGN1412 that were comparable with those of HD T cells. This strongly suggests that the HD preculture enhances responses through a direct effect upon the monocyte population independent of any change in the responsiveness of the T cells themselves 9 . This is further supported by experiments using fresh PBMCs in which T cells were responsive to TGN1412 in the presence of autologous HD but not LD monocytes (Supplementary Figure 5) . This is in agreement with a recent study in which cross-linking anti-IgG modified responsiveness to TGN1412 irrespective of whether the T cells were isolated from HD or LD PBMCs 10 . Together these observations suggest that enhanced tonic TCR signalling during HD preculture 24, 25 is not critical for responsiveness to TGN1412 in vitro. However, our observations are in accordance with previous findings in which monocyte maturation in HD PBMC cultures mediates full T-cell responsiveness to For . Work with CD40 has shown that simply cross-linking the receptors is sufficient for activity and that no downstream signalling is required 31, 32, 33 . Whether the same holds true for TGN1412 and CD28 remains to be confirmed.
Although in HD precultured PBMCs TGN1412 activity was dependent on monocytes, activity could also be mediated by B cells when added at a high enough frequency. However, monocytes were more active on a cell:cell basis. While this may be due to the higher expression of FcγRIIb on monocytes, it may be associated with qualitative differences between the two cell types. One intrinsic difference is their expression of alternate FcγRIIb isoforms, with B cells expressing predominantly b1 and monocytes b2 ( Figure 4C ). The b1 isoform prevents association with clathrin-coated pits and internalization when co-ligated with the BCR 34, 35 . In contrast, the b2 isoform localises to clathrin-coated pits and adopts a more clustered appearance (Manfredi et al., unpublished data). It is possible that the more clustered b2 isoform on monocytes is a more efficient cross-linker giving more potent CD28 signalling. Our study offers an insight on how TGN1412 may be cross-linked in vivo leading to adverse events and has implications for in vitro testing of a wider range of therapeutic mAb targeting T cell co-stimulatory molecules. Furthermore, we propose that TGN1412 can be specifically re-defined as an FcγR-dependent superagonist, and together our observations indicate that FcγRIIb-targeted Fc-engineering of mAb such as TGN1412 which target T-cell costimulatory molecules may be employed in order to improve their safe clinical use. Analysis in D and E was using a FACSCalibur. 
